Current Status and Progress in Molecular Imaging of Non-small Cell Lung Cancer for Molecular Targeted EGFR-TKI Treatment Sensitivity and Treatment Tolerance Prediction

VernacularTitle:非小细胞肺癌分子靶向EGFR-TKI治疗敏感性与治疗耐受性预测筛选的分子显像研究现状及进展
Author: DAI DONG ¹ ; XU WENGUI ; WANG QI ; LI XIAOFENG ; ZHU YANJIA
Author Information

1. 300060天津,天津医科大学肿瘤医院分子影像及核医学诊疗科,国家肿瘤临床医学研究中心,天津市肿瘤防治重点实验室
Keywords: Lung neoplasms; EGFR; Targeted therapy; PET/CT; Molecular imaging
From: Chinese Journal of Lung Cancer 2017;20(12):852-856
CountryChina
Language:Chinese
Abstract: More than 80％ of lung cancer is non-small cell lung cancer (NSCLC),and the epidermal growth factor receptor (EGFR)-mediated signaling pathway is closely related to the occurrence and development of NSCLC.Small molecule EGFR-tyrosine kinase inhibitors (EGFR-TKI) targeting EGFR have been used in the clinical treatment of NSCLC,and positron emission tomography/computed tomgraphy (PET/CT) imaging can noninvasively monitor the expression and mutation status of EGFR in patients with NSCLC.18F-FDG PET/CT imaging has predictive value for the activation of EGFR mutation and EGFR-TKI treatment efficacy,and in vivo can be directly observed drugs and systemic tumor targeting EGFR combined with the specific circumstances,by PET/CT imaging before and after treatment,to achieve dynamic monitoring,guide the therapy before treatment and treatment of sensitive population screening process,to achieve NSCLC EGFR-TKI precise treatment is essential.